ACCELERATING “BIO”PHARMACEUTICAL DEVELOPMENT

An innovative SPPS technology platform BIOSIMILARS / BIOBETTERS

When GMP production of protein by chemical synthesis becomes a reality:

• SYNPROSIS has developed an innovative way to produce non-glycosylated proteins by chemical synthesis, which is a HIGHLY competitive process when compared to bioproduction. • Some of these bioproducts are targets for the development of biosimilars or biobetters. • Synprosis provides access to these products, and in particular: Interferons, growth factors, in native form or pegylated.

Why chemical synthesis of proteins:

• Recombinant expression of proteins is difficult due to the inherent sequence variability of each protein and the lack of a common platform required to produce them. • “Synprosis SPPS technology” provides access to a wide range of proteins traditionally expressed in E Coli.

• Synprosis focuses his development program to proteins ranging from 150 to 250 aa in length.

• Advantages:

- Fast development process – Products with high quality and high reproducibility – Competitive COGS

SYNPROSIS has currently 8 biosimilar molecules in development. We are actively seeking co-development partners for these and other new biosimilar programs.  

Products Pipeline:

- Non glycosylated Interferons native or pegylated – GCSF, native or pegylated